Published in Am J Gastroenterol on January 26, 2010
Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology (2013) 1.92
Surveillance for low-grade dysplastic Barrett's oesophagus: one size fits all? World J Surg (2015) 1.45
Comparison of endoscopic and clinical characteristics of patients with familial and sporadic Barrett's esophagus. Dig Dis Sci (2011) 1.43
A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus. PLoS Comput Biol (2016) 1.38
Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia. Gastroenterology (2015) 1.10
The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer (2012) 1.06
Epigenetic biomarkers in esophageal cancer. Cancer Lett (2012) 1.01
Natural history of Barrett's esophagus. World J Gastroenterol (2012) 0.93
Mitigating fluorescence spectral overlap in wide-field endoscopic imaging. J Biomed Opt (2013) 0.90
Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. Dig Dis Sci (2012) 0.88
Advances in Endoscopic Visualization of Barrett's Esophagus: The Role of Confocal Laser Endomicroscopy. Gastroenterol Res Pract (2012) 0.84
A Multiscale Model Evaluates Screening for Neoplasia in Barrett's Esophagus. PLoS Comput Biol (2015) 0.84
Multiphoton tomographic imaging: a potential optical biopsy tool for detecting gastrointestinal inflammation and neoplasia. Cancer Prev Res (Phila) (2012) 0.83
Gastroesophageal reflux disease and tooth erosion. Int J Dent (2011) 0.83
A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus. Dig Dis Sci (2015) 0.82
MicroRNA alterations in Barrett's esophagus, esophageal adenocarcinoma, and esophageal adenocarcinoma cell lines following cranberry extract treatment: Insights for chemoprevention. J Carcinog (2011) 0.80
Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer (2014) 0.80
Diagnosis and management of Barrett's esophagus. Surg Clin North Am (2012) 0.78
Long-term results of ablation with antireflux surgery for Barrett's esophagus: a clinical and molecular biologic study. Surg Endosc (2012) 0.78
Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus. World J Gastroenterol (2015) 0.75
Surveillance in Barrett esophagus. J Med Life (2014) 0.75
Occupational exposure and the risk of Barrett's esophagus: a case-control study. Dig Dis Sci (2013) 0.75
Esophageal Cancer Prevention. Gastroenterol Hepatol (N Y) (2016) 0.75
Low grade dysplasia in Barrett's esophagus: Should we worry? World J Gastrointest Pathophysiol (2014) 0.75
Differences in the Characteristics of Barrett's Esophagus and Barrett's Adenocarcinoma between the United States and Japan. ISRN Gastroenterol (2013) 0.75
Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett's esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence. United European Gastroenterol J (2015) 0.75
Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview. Ann Gastroenterol (2016) 0.75
Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet (2005) 17.75
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol (2006) 12.80
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst (2005) 8.90
The epidemiology of obesity. Gastroenterology (2007) 8.35
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol (2008) 7.94
Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71
Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology (2001) 5.80
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc (2005) 4.78
Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology (2000) 4.74
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature (2006) 4.57
Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med (2005) 4.52
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol (2001) 4.16
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology (2003) 3.90
Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res (2001) 3.70
Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol (1988) 3.67
Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's Esophagus. Gastroenterology (2008) 3.42
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med (2003) 3.30
Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology (2002) 3.28
Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol (2004) 3.15
Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.06
Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2007) 3.00
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol (2000) 2.99
Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc (2007) 2.77
Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 2.59
Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut (2008) 2.51
Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol (2009) 2.46
Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology (2003) 2.42
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology (2001) 2.34
The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.34
Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology (2001) 2.30
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol (1999) 2.26
Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst (2000) 2.24
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol (1997) 2.23
Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol (2001) 2.21
Central adiposity and risk of Barrett's esophagus. Gastroenterology (2007) 2.20
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17
Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut (2002) 2.16
Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res (2004) 2.15
Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2001) 2.13
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 2.07
Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05
Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg (2003) 2.03
Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology (1993) 2.00
Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust (2004) 1.97
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol (2001) 1.94
p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol (2001) 1.91
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87
Tumour biology: Policing of oncogene activity by p53. Nature (2006) 1.86
The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin Gastroenterol Hepatol (2008) 1.85
The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol (2000) 1.84
Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest (1996) 1.81
Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol (2002) 1.81
The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res (2004) 1.76
Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol (2003) 1.73
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res (2003) 1.62
p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol (2002) 1.58
Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer (1993) 1.54
Low-grade dysplasia in Barrett's esophagus - an innocent bystander? Pro. Endoscopy (2007) 1.50
Meta analysis: Cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther (2007) 1.50
Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol (2002) 1.49
Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol (2008) 1.46
Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc (1999) 1.45
Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg (2005) 1.40
p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology (2002) 1.38
Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol (2005) 1.37
Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol (2007) 1.30
Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin Cancer Res (2003) 1.26
Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol (2004) 1.24
Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol (2005) 1.23
Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene (2006) 1.22
Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol (2006) 1.20
Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol (1999) 1.18
Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.17
Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer (1995) 1.16
Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2002) 1.14
DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry (1998) 1.13
Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2006) 1.12
Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol (1997) 1.12
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One (2008) 1.12
Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endosc (2007) 1.11
The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus. Gut (1993) 1.11
Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol (2008) 1.10
The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. J Mol Diagn (2006) 1.09
Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy (2007) 1.09
Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2008) 1.08
Cell proliferation in three types of Barrett's epithelium. Gut (1980) 1.08
DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues. Am J Gastroenterol (2004) 1.08
Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol (2008) 1.06
Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci (1989) 1.06
Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res (1996) 1.06
Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. Am J Clin Pathol (2007) 1.03
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc (2005) 4.78
Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc (2007) 3.53
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc (2007) 3.23
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology (2002) 2.88
Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology (2007) 2.86
Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc (2007) 2.77
The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc (2006) 2.71
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc (2008) 2.51
Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc (2011) 2.51
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol (2009) 2.46
Component Level Modular Design of a Solid State X-ray Image Intensifier for an M×N Array. IEEE Nucl Sci Symp Conf Rec (1997) (2010) 2.28
Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc (2010) 2.28
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology (2011) 2.27
Water quality modelling of the river Yamuna (India) using QUAL2E-UNCAS. J Environ Manage (2006) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2010) 2.24
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst (2002) 2.13
Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) (2008) 2.11
Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol (2013) 2.10
Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc (2007) 2.06
History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology (2010) 2.05
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Narrow-band imaging colonoscopy--a pilot feasibility study for the detection of polyps and correlation of surface patterns with polyp histologic diagnosis. Gastrointest Endosc (2007) 1.95
Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology (2013) 1.92
Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology (2009) 1.88
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87
Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc (2005) 1.86
Correlation between narrow band imaging and nonneoplastic gastric pathology: a pilot feasibility trial. Gastrointest Endosc (2008) 1.85
Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol (2003) 1.82
Overutilization of endoscopic surveillance in nondysplastic Barrett's esophagus: a multicenter study. Gastrointest Endosc (2011) 1.82
Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol (2009) 1.74
Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology (2013) 1.72
Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol (2006) 1.72
Preliminary accuracy and interobserver agreement for the detection of intraepithelial neoplasia in Barrett's esophagus with probe-based confocal laser endomicroscopy. Gastrointest Endosc (2010) 1.69
Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc (2009) 1.66
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res (2009) 1.65
Accuracy of in vivo optical diagnosis of colon polyp histology by narrow-band imaging in predicting colonoscopy surveillance intervals. Gastrointest Endosc (2011) 1.61
Recognition of surface mucosal and vascular patterns of colon polyps by using narrow-band imaging: interobserver and intraobserver agreement and prediction of polyp histology. Gastrointest Endosc (2009) 1.60
Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity (Silver Spring) (2013) 1.60
Initial evaluation of the efficacy and safety of endoscopic ultrasound-guided direct Ganglia neurolysis and block. Am J Gastroenterol (2007) 1.58
Accuracy of narrow-band imaging in predicting colonoscopy surveillance intervals and histology of distal diminutive polyps: results from a multicenter, prospective trial. Gastrointest Endosc (2013) 1.58
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology (2012) 1.58
Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol (2013) 1.56
Prospective assessment of EUS criteria for lymphadenopathy associated with rectal cancer. Gastrointest Endosc (2008) 1.55
High accuracy of narrow band imaging without magnification for the real-time characterization of polyp histology and its comparison with high-definition white light colonoscopy: a prospective study. Am J Gastroenterol (2009) 1.50
Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology (2010) 1.47
Biomarkers in gastrointestinal cancers. Am J Gastroenterol (2008) 1.45
Higher adenoma detection rates with cap-assisted colonoscopy: a randomised controlled trial. Gut (2011) 1.45
A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology (2007) 1.44
Randomized, controlled trial of standard-definition white-light, high-definition white-light, and narrow-band imaging colonoscopy for the detection of colon polyps and prediction of polyp histology. Gastrointest Endosc (2011) 1.44
Visible endoscopic and histologic changes in the cardia, before and after complete Barrett's esophagus ablation. Gastrointest Endosc (2005) 1.44
Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology (2012) 1.43
Effect of proton pump inhibitor therapy on inflammatory changes in the gastric cardia (carditis). Dig Dis Sci (2007) 1.39
MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.35
Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology (2007) 1.34
Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One (2010) 1.33
Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol (2011) 1.32
A comparative study of endoscopic ultrasound guided fine needle aspiration with and without a stylet. Dig Dis Sci (2011) 1.32
The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc (2005) 1.28
Utility of endoscopic ultrasound in the diagnosis of aberrant right subclavian artery. J Gastroenterol Hepatol (2007) 1.27
Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One (2012) 1.26
Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol (2004) 1.24
A prospective, single-blind, randomized, controlled trial of EUS-guided FNA with and without a stylet. Gastrointest Endosc (2011) 1.23
The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on imaging in Barrett's Esophagus. Gastrointest Endosc (2012) 1.23
Novel probe-based confocal laser endomicroscopy criteria and interobserver agreement for the detection of dysplasia in Barrett's esophagus. Am J Gastroenterol (2011) 1.23
Safety of prior endoscopic mucosal resection in patients receiving radiofrequency ablation of Barrett's esophagus. Clin Gastroenterol Hepatol (2011) 1.22
Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol (2007) 1.20
Standards for gastroenterologists for performing and interpreting diagnostic computed tomographic colonography. Gastroenterology (2007) 1.20
Adequacy of esophageal squamous mucosa specimens obtained during endoscopy: are standard biopsies sufficient for postablation surveillance in Barrett's esophagus? Gastrointest Endosc (2011) 1.18
MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2013) 1.18
EUS-FNA assessment of extramesenteric lymph node status in primary rectal cancer. Gastrointest Endosc (2011) 1.17
Endoscopic ultrasound-guided trucut biopsy of the cyst wall for diagnosing cystic pancreatic tumors. Clin Gastroenterol Hepatol (2005) 1.16